Feb 12, 2026 04:05PM
Feb 12, 2026 04:05PM
Jan 20, 2026 07:30AM
Jan 20, 2026 07:30AM
Jan 8, 2026 12:08PM
Dec 11, 2025 02:35PM
Dec 11, 2025 02:35PM Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium
Nov 17, 2025 04:05PM
Nov 12, 2025 04:01PM
Oct 18, 2025 04:30AM
Oct 18, 2025 04:30AM
Sep 9, 2025 04:01PM
Sep 9, 2025 04:01PM
Aug 27, 2025 04:05PM Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA’s Real-Time Oncology Review Program
Aug 18, 2025 06:47AM
Aug 14, 2025 04:01PM
Jul 28, 2025 07:00AM
Jul 28, 2025 07:00AM
Dec 11, 2024 07:05AM
Dec 11, 2024 07:05AM
May 30, 2024 02:29PM Stifel Reiterates Buy Rating on Celcuity Inc (CELC)
May 30, 2024 07:05AM
May 30, 2024 07:00AM
Nov 13, 2023 07:05AM
Aug 22, 2023 04:01PM
Mar 23, 2023 04:00PM
Dec 7, 2022 04:00PM
Nov 10, 2022 04:00PM Celcuity Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Aug 11, 2022 04:00PM
Jul 18, 2022 05:12PM
Jul 18, 2022 05:10PM
May 16, 2022 04:00PM
Mar 23, 2022 04:00PM
Jan 18, 2022 07:31AM
Jan 18, 2022 07:30AM Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate Update
Dec 10, 2021 09:31AM
Dec 10, 2021 09:30AM
Nov 15, 2021 08:00AM
Nov 8, 2021 04:00PM
Oct 18, 2021 04:11PM
Oct 18, 2021 04:09PM
Aug 9, 2021 04:00PM Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Jun 29, 2021 09:27AM
Jun 9, 2021 09:10AM
May 10, 2021 04:00PM
Apr 12, 2021 04:00PM
Apr 9, 2021 09:31AM
Apr 8, 2021 05:45PM
Apr 8, 2021 04:07PM Celcuity (CELC) Reports Preliminary Data from Phase 1b Trial of Gedatolisib plus Ibrance and Endocrine Therapy for Patients with ER+/HER2- Metastatic Breast Cancer and Provides Corporate Update
Apr 8, 2021 04:05PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All